Leveraging human genetics to identify safety signals prior to drug marketing approval and clinical use

INTRODUCTION: When a new drug or biologic product enters the market, its full spectrum of side effects is not yet fully understood, as use in the real world often uncovers nuances not suggested within the relatively narrow confines of preapproval preclinical and trial work. OBJECTIVE: We describe a...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Drug Saf
Auteurs principaux: Jerome, Rebecca N., Joly, Meghan Morrison, Kennedy, Nan, Shirey-Rice, Jana K., Roden, Dan M., Bernard, Gordon R., Holroyd, Kenneth J., Denny, Joshua C., Pulley, Jill M.
Format: Artigo
Langue:Inglês
Publié: 2020
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7398579/
https://ncbi.nlm.nih.gov/pubmed/32112228
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40264-020-00915-6
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires